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Abstract
Background: Transforming growth factor-β (TGF-β) and bone morphogenetic proteins (BMPs) utilize parallel and 
related signaling pathways, however the interaction between these pathways in bone remains unclear. TGF-β 
inhibition has been previously reported to promote osteogenic differentiation in vitro, suggesting it may have a 
capacity to augment orthopaedic repair. We have explored this concept using an approach that represents a template 
for the testing of agents with prospective orthopaedic applications.
Methods: The effects of BMP-2, TGF-β1, and the TGF-β receptor (ALK-4/5/7) inhibitor SB431542 on osteogenic 
differentiation were tested in the MC3T3-E1 murine pre-osteoblast cell line. Outcome measures included alkaline 
phosphatase staining, matrix mineralization, osteogenic gene expression (Runx2, Alp, Ocn) and phosphorylation of 
SMAD transcription factors. Next we examined the effects of SB431542 in two orthopaedic animal models. The first was 
a marrow ablation model where reaming of the femur leads to new intramedullary bone formation. In a second model, 
20 μg rhBMP-2 in a polymer carrier was surgically introduced to the hind limb musculature to produce ectopic bone 
nodules.
Results: BMP-2 and SB431542 increased the expression of osteogenic markers in vitro, while TGF-β1 decreased their 
expression. Both BMP-2 and SB431542 were found to stimulate pSMAD1 and we also observed a non-canonical 
repression of pSMAD2. In contrast, neither in vivo system was able to provide evidence of improved bone formation or 
repair with SB431542 treatment. In the marrow ablation model, systemic dosing with up to 10 mg/kg/day SB431542 
did not significantly increase reaming-induced bone formation compared to vehicle only controls. In the ectopic bone 
model, local co-administration of 38 μg or 192 μg SB431542 did not increase bone formation.
Conclusions: ALK-4/5/7 inhibitors can promote osteogenic differentiation in vitro, but this may not readily translate to 
in vivo orthopaedic applications.
Background
Bone Morphogenetic Proteins (BMPs) are critical in the
formation of cartilage and bone. Osteogenic BMPs, such
as BMP-2, and -7 are widely recognized to promote an
osteogenic response [1]. Transforming Growth Factor-β
(TGF-β) belongs to the same superfamily as the BMPs,
alt hough its role in bone is less clear . Bot h BMP s and
TGF-β bind to related Type I receptors (also known as
Activin Receptor-like Kinases or ALKs) and Type II
receptors and activate downstream SMAD signaling
pathways [2-4]. The osteogenic BMPs can bind to ALKs
1/2/3/6 and BMPRII or ActRII to induce phosphorylation
of the receptor-regulated SMADs (R-SMADs) 1/5/8. In
the case of TGF-β and the non-osteogenic BMPs, ligand
binding to receptors such as ALKs 4/5/7 and TβRII
induces phosphorylation of R-SMADs 2/3.
There is conflicting evidence on the effects of TGF-β
signaling on bone formation. TGF-β isoforms are
robustly expressed during the early stages of bone healing
[5,6], and exogenous TGF-β has been purported to aug-
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ment bone markers in cultured human osteoblasts [7]
and can lead to improvements in bone repair in ortho-
paedic animal models [8-10]. However, in cultured
murine cell lines, TGF-β acting through SMAD3 was
reported to antagonize osteogenesis [11,12] and compa-
rable findings were found in human mesenchymal stem
cells [13]. Further work suggests that exogenous TGF-β
can delay osteogenesis in favor of chondrogenesis [14]. In
addition to direct effects on osteogenic differentiation,
TGF-β may also lead to increased fibrosis. In rodent dis-
traction osteogenesis and fracture models, TGF-β1 and
TGF-β2 treatment (respectively) did not lead to improved
outcomes but did result in increased fibrous and cartilage
tissue [15,16]. In these studies, inflammation and edema
were also reported as unfavorable side-effects.
TGF-β signaling has also been linked to other fibrotic
conditions, such as the genetic disorder Marfan syn-
drome. Animal models with aberrant TGF-β signaling
have been successfully treated with TGF-β neutralizing
antibody or with Losartan, a small-molecule angiotensin
II AT1 receptor blocker (ARB) [17-19]. ARBs are now
under trial for Marfans syndrome [20], and may be appli-
cable for other TGF-β related disorders. However, the
affects of ARBs on TGF-β protein expression are indirect
and do not appear to translate to bone [21], thus making
these agents less attractive for orthopaedic applications.
In contrast, a novel synthetic compound, SB431542, has
been shown to rapidly and selectively inhibit ALK-4/5/7
but not ALK-2/3/6 kinase activity [22]. This enables the
blockade of the classical TGF-β-SMAD2/3 signaling
pathway whilst allowing osteogenic BMP-SMAD1/5/8
signaling.
In a seminal study by Maeda et al. (2004), SB431542
repression of TGF-β signaling was found to enhance
osteoblastic differentiation in BMP-2 treated C2C12
myoblasts [23]. Osteoblastic differentiation and matrix
mineralization were also increased in cultured human
mesenchymal stem cells. Based on these in vitro findings,
we speculated that this compound may also be able to
positively influence bone formation or healing. As a puta-
tive anti-fibrotic agent, SB431542 could have additional
benefits in the context of orthopaedic repair where fibro-
sis is problematic.
In this study we have used both in vitro and in vivo
methods suitable for the rapid screening of compounds
specifically for orthopaedic applications. These assays
represent a systematic approach that can be readily
applied to other putative pro-osteogenic agents. In cell
culture experiments, we treated the MC3T3-E1 pre-
osteoblast cell line with purified recombinant BMP-2,
purified TGF-β1, and the TGF-β receptor inhibitor
SB431542, individually and in combination. Outcome
measures included alkaline phosphatase (AP) and miner-
alization staining, osteogenic gene expression, and activa-
tion of downstream SMAD signaling pathways. Next, we
attempted to translate the effects of TGF-β inhibition
using animal models. This included a marrow ablation
model (where intramedullary reaming produces bone
formation over a 10-day period via intramembranous
ossification), and BMP-2 implantation (where ectopic
bone nodules are induced in muscle over 3 weeks via
endochondral ossification). This study design represents
a straightforward methodology for testing prospective
orthopaedic agents.
Methods
Cell culture methods
MC3T3-E1 pre-osteoblasts were grown in α-MEM media
containing 10% FBS (Invitrogen, Carlsbad, CA, USA).
Passage number 20 cells were used, and cultured for no
more than 2 weeks prior to initiating differentiation.
Osteogenic differentiation was instigated by supplement-
ing media with 50 mg/L ascorbic acid and 10 mM β-glyc-
erophosphate (Sigma Aldrich, St Louis, MO, USA). All
culture media contained 2 mM L-glutamine, and antibi-
otics (100 units/ml penicillin and 0.1 mg/ml streptomy-
cin) (Invitrogen). Cultures were grown in 37°C incubators
at 5% CO2 with media changes every 2-3 days. For stain-
ing experiments cells were plated in 48-well plates at 5 ×
104 cells/well. For cDNA or protein collection experi-
ments cells were seeded in 6-well plates at 2 × 105 cells/
well. Cells were plated overnight and were sub-confluent
prior to the addition of drugs or recombinant proteins.
Recombinant proteins and drugs
Recombinant human BMP-2 (rhBMP-2) (Medtronic Aus-
tralasia, North Ryde, NSW, Australia) was solubilized in
sterile water at stock concentrations of 100 μg/ml. Trans-
forming growth factor-beta 1 (TGF-β1) was purchased
from Sigma Aldrich (T1654), and reconstituted at 1 μg/
ml in filtered 0.1% BSA in 4 mM HCl. The ALK-4/5/7
inhibitor SB431542 was purchased from Sigma Aldrich
(S4317) and solubilized in dimethylsulfoxide (DMSO) at
stock concentration of 10 mM. For in vitro experiments,
all wells received the same volume of DMSO (<0.1%) to
avoid the confounding effects of DMSO on osteogenic
differentiation [24]. PTH(1-34)  peptide was purchased
from Auspep (Parkville, VIC, USA).
Alkaline phosphatase (AP) and Alizarin Red S staining
Prior to staining, all cells were washed with PBS and fixed
with 4% paraformaldehyde (PFA). AP staining was per-
formed using a solution containing 0.5 mg/ml naphthol
AS-BI phosphate (Sigma Aldrich), 0.5 mg/ml Fast Blue
(Sigma Aldrich), 10% N,N-dimethylformamide (Sigma
Aldrich), 0.5% MgCl2 in 0.1 M Tris (pH 9.4) for 10 min at
room temperature [25]. Mineralization of calcium depos-
its was assessed by Alizarin Red S staining (40 mM, pHSchindeler et al. BMC Musculoskeletal Disorders 2010, 11:105
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4.2) (LabChem, Pittsburgh, PA, USA) for 10 min at room
temperature, followed by multiple washes with distilled
water to remove background staining [26].
RNA extraction, cDNA preparation, and real-time 
quantitative PCR (qPCR)
Total RNA was isolated using TRIZOL reagent (Invitro-
gen). Equivalent amounts of total RNA were used to syn-
thesize cDNA by reverse-transcription using Superscript
III Reverse Transcriptase (Invitrogen). All samples were
amplified using the SYBR Green PCR reagent kit (Inte-
grated Sciences, Chatswood, NSW, Australia). PCR was
performed on the Rotor-Gene 3000 (Corbett Life Science,
Sydney, NSW, Australia). PCR primer sequences and
amplification conditions are as previously published [27].
PCR reactions were performed in quadruplicate and nor-
malized to the housekeeping Gapdh. Data are presented
as mean fold induction relative to untreated cells, with
the standard deviation shown in parentheses.
Western blotting
Cell extracts were harvested in SDS sample buffer, dena-
tured at 95°C for 10 min, separated by electrophoresis on
a 1% SDS-P AGE gel, and then transferred by semi-dry
electroblotting to PVDF membrane (Millipore, Billerica,
MA, USA) [27]. Immunoblotting was performed with
anti-Smad1 and anti-Smad2 (Zymed/Invitrogen), anti-
pSmad1 and anti-pSmad2 (Cell Signaling Technology,
Boston, MA, USA), and α-Tubulin (Sigma-Aldrich) anti-
bodies. Horseradish peroxidase-conjugated donkey anti-
rabbit IgG and sheep anti-mouse IgG secondary antibod-
ies were used (GE Healthcare, Little Chalfont, Bucking-
hamshire, UK). Chemiluminescence reagents (New
England Biolabs, Ipswich, MA, USA) were used to visual-
ize the blots on X-ray film.
Surgical models
Experiments using mice were approved by the SWAHS
Animal Ethics Committee (Protocol 5031). In all studies,
8-10 week old C57BL6/J mice were used and anesthesia
was induced with inhaled isofluorane. Pain was managed
using buprenorphine (0.05-0.1 mg/kg) subcutaneously
(s.c.) postoperatively (then every 12 hours as required).
Dehydration was managed by saline injection as required.
Marrow Ablation Model New intramedullary bone was
induced by femoral reaming as previously described in
rats [28] and mice [29]. An incision was made on the right
hind leg lateral to the knee and a 25G needle pushed
through the cortex of the distal femur between the inter-
condyles and unilaterally up the medullary canal to
loosen the marrow. This needle was removed and 0.1 ml
of saline was injected into the cavity to flush out the mar-
row using a 30G needle. The wound was closed using 5-0
nylon suture (Ethicon). Mice were dosed s.c. daily with
SB431542 in DMSO from the day of surgery until sacri-
fice at day 10. Control groups received an equivalent vol-
ume of vehicle (DMSO) or the bone inducing agent 25
μg/kg/day PTH1-34 (Auspep). In an initial study, 1 mg/kg/
day SB43152, DMSO control, and PTH1-34 groups were
examined (N = 6). In a second study, a wider dose range
was used of 0.1 mg/kg/day, 1 mg/kg/day, and 10 mg/kg/
day SB431542 (N = 6) with DMSO controls (N = 6) and a
nominal number of repeated PTH(1-34) controls (N = 2).
BMP-2 Implantation Model New bone formation in a
quadriceps muscle pouch was assayed after 3 weeks fol-
lowing the implantation of a BMP-2 containing pellet.
Pellets containing 20 μg recombinant human BMP-2
(Medronic Australasia) and 0 μg, 38 μg, or 192 μg
SB431542 (Sigma-Aldrich) were manufactured by solubi-
lizing Poly-(D, L-lactic acid) polymer (viscosity 0.55-0.75,
average Mw 75000-12000, Sigma-Aldrich) and drugs in
ethyl acetate (analytical reagent grade, Chem Supply, Gill-
man, SA, Australia) and evaporating the solvent under
vacuum. The BMP-2 dose was previously determined
empirically using this polymer delivery system and the
ratio of BMP-2/SB431542 was based on in vitro efficacy.
Pellets were molded by compression in a modified 0.3 ml
syringe. Pellets were surgically implanted by a surgeon
experienced in mice using published methods [25].
Group sizes of N = 8 were used.
Radiographic analysis
The bone formed in both models was examined at the
experimental endpoint using a digital X-ray machine
(Faxitron X-ray Corp., Wheeling, IL, United States).
To quantify the total bone mineral content (BMC) in
the distal region of reamed and unreamed femora,
peripheral Quantitative Computed Tomography (pQCT)
and analysis was performed using a XCT-960A scanner
(Stratec Medizintechnik, Pforzheim, Germany). A region
spanning the midshaft to the distal femur was selected
after a pre-scan and measurements were taken from ten 2
× 5 × 0.2 mm slices using a red collimation mask. These
values were averaged and for each mouse the reaming-
induced bone was normalized to the non-operated limb.
To quantify the total bone volume (BV, mm3) in each
BMP-induced bone pellet, micro Computed Tomography
(microCT) scanning was performed using SkyScan 1174
compact microCT scanner (SkyScan, Kontich, Belgium).
The X-ray source voltage was set at 50 kV and beam cur-
rent set at 800 μA. To minimize the beam hardening arti-
facts a 0.5 mm aluminum X-ray beam filter was used to
attenuate soft X-rays at the source. Samples were scanned
at 8.7 μm resolution and 0.4° angular increments. Acqui-
sition time was approximately 30 minutes/specimen. BV
analysis was performed using CTAnalyser software, ver-
sion 1.9.2.3 (SkyScan). A global grey value threshold rep-
resenting new bone formation (47-255) was defined and
applied to all samples. Total bone volume was calculated
for the entire pellet. Representative three-dimensionalSchindeler et al. BMC Musculoskeletal Disorders 2010, 11:105
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bone pellets were reconstructed with transaxial slices
(100 slices) of the pellet's mid-section, using CTVol Real-
istic Visualisation software version 2.1.0.0 (SkyScan).
For statistical analysis of in vivo data, group sizes <10
necessitated stringent non-parametric statistical tests.
Kruskal Wallis and Mann Whitney U tests were per-
formed using SPSS Statistics version 17 (SPSS Inc., Chi-
cago, IL, United States).
Histological Analysis
Samples were harvested and fixed in 4% PFA and stored
in 70% ethanol. Bone was decalcified at room tempera-
ture on a shaker in 0.34 M EDTA (pH 8.0) containing
0.5% PFA for 3 days, followed by 38 days in 0.34 M EDTA
(pH 8.0) with changes every 3-4 days. Samples were
embedded in paraffin blocks and 5 mm-thick sections
cut. Sections were stained with Picrosirius red and Alcian
blue for bone and cartilage.
Results
In vitro interactions of TGF-β and BMP signaling pathways
To verify the capacity of TGF-β signaling to modulate
osteogenesis we tested BMP-2, TGF-β, and the ALK-4/5/
7 inhibitor SB431542 in the MC3T3-E1 pre-osteoblastic
cell line that is commonly employed to model osteoblast
differentiation. Without treatment, MC3T3-E1 cells
express the alkaline phosphatase (AP) enzyme at day 3,
and matrix mineralization was seen at day 10. Matrix
mineralization in particular is an unambiguous marker of
mature bone cell function. Colorimetric assays were
selected to facilitate rapid screening. To further validate
the colorimetric assays, qPCR markers of early osteoblast
differentiation were also examined at 3 days and mature
markers at 10 days.
Dose response curves were performed for individual
agents (data not shown) and doses that showed sub-max-
imal and no toxic effects when given individually were
selected for further analysis in combination. As expected,
AP (Figure 1A) and mineralization stains (Figure 1B)
were suppressed by exogenous TGF-β1 treatment and
augmented with BMP-2 treatment. The SB431542 inhibi-
tor was found to be sufficient to promote osteogenic dif-
ferentiation in isolation and was able to produce additive
effects when co-treated with BMP-2. Neither SB431542
nor BMP-2 could individually overcome the repressive
effects of TGF-β1 on osteogenesis, although this was
observed when they were used in combination. The com-
parable outcomes seen for AP and mineralization indi-
cate these agents do not have differing effects on early
osteoblast differentiation and mature osteoblast function.
In a subsequent experiment, cDNA was synthesized
from treated cells and this was analyzed by qPCR. Bone
genes included the early osteogenic/chondrogenic com-
mitment factor Runx2  (Table A1A), the osteoblastic
marker  Alp  (Table B1B), and the mature bone marker
osteocalcin (Ocn) (Table C1C). Gene expression profiles
reflected the AP and mineralization staining data results
with SB431542 able to augment osteogenesis alone and in
combination with BMP-2. These data reinforce the con-
cept that blockade of the ALK-4/5/7 receptors can aug-
ment the differentiation of committed osteoprogenitors
in vitro.
Modulation of R-SMAD activity
While BMP and TGF-β can mediate strong transient
changes in SMAD activity, particularly in serum starved
cells, we sought to determine the sustained activation of
SMADs concomitant with osteogenic differentiation as
has been examined previously [23]. The phosphorylation
status of SMAD1 and SMAD2 were assayed as represen-
tative of the activity of the osteogenic (BMP-stimulated)
and non-osteogenic (TGF-β1 stimulated) R-SMADs
respectively. Consistent with the onset of AP expression,
samples were collected at day 3. The phosphorylated
(pSMAD1, pSMAD2) forms of the protein were exam-
ined by western blotting, with total SMAD1 and α-Tubu-
lin included as a loading controls (Figure 1C). BMP-2
increased pSMAD1 levels, and also reduced pSMAD2
levels. While the classical model for TGF-β1 signaling
indicates that it acts primarily via pSMAD2, we observed
in the MC3T3-E1 system that exogenous TGF-β1 treat-
ment suppressed pSMAD1 and that pSMAD2 levels were
unchanged. SB431542 both reduced pSMAD2 and
Figure 1 Effects of TGF-β, BMP-2, and SB431542 on cultured 
MC3T3-E1 pre-osteoblasts. Cells were grown and treated with 
agents (50 ng/ml BMP-2, 5 ng/ml TGF-β1, and 1 μM or 5 μM SB431542) 
and subjected to a rapid staining protocol that visually indicated os-
teogenic differentiation at 3 days (A, Alkaline Phosphatase) or matrix 
mineralization at 10 days (B, Alizarin Red S). These results confirmed 
that SB431542 can promote both early osteoblast differentiation and 
mature osteoblast function in vitro, and these results were indepen-
dently repeated. To confirm mechanistically the effects of these com-
pounds on downstream signaling (SMAD activity), Western analysis 
was performed on day 3 samples using pSMAD1, pSMAD2, SMAD1, 
SMAD2 and α-Tubulin antibodies. These data indicated that BMP-2 
and SB431542 could promote SMAD1 phosphorylation and reduce 
SMAD2 phosphorylation.Schindeler et al. BMC Musculoskeletal Disorders 2010, 11:105
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increased pSMAD1, suggesting a sophisticated signaling
mechanism for this compound.
Effects of SB431542 in a murine marrow ablation model
Healthy C57BL6/J mice underwent a surgical procedure
where the marrow cavity was reamed to promote fibrosis
followed by new bone formation. An in vivo dose of 1 mg/
kg/day SB431542 was initially extrapolated from the
effective 2 μg/ml (5 μM) in vitro dose based on the ratio
of systemic PTH1-34 (25 μg/kg/wk) to an effective in vitro
dose of 50 ng/ml known to stimulate primary osteoblast
differentiation (data not shown).
In an initial screen to validate the model system, mice
were given DMSO vehicle alone, 25 μg/kg/day PTH(1-34),
or 1 mg/kg/day SB431542 with all drugs given s.c. Hind
limbs were harvested after 10 days and analyzed by X-ray,
histology, and pQCT scanning. X-ray images showed the
presence of additional mineralized tissue within the
intramedullary canals of reamed limbs, indicative of new
bone formation (Figure 2A). Quantification by pQCT
showed consistent increases in BMC in the reamed limbs
compared to the non-operated limbs of DMSO treated (P
= 0.055), SB431542 treated (P = 0.055), and PTH(1-34)
treated (P = 0.004) animals. These differences were more
evident in terms of new bone directly below the growth
plate in histological sections (Figure 2A). Nevertheless,
neither pQCT nor histology showed any additional
improvement in marrow ablation-induced new bone for-
mation with SB431542 treatment (12% decrease in BMC
with SB431542 over DMSO, P = 0.26). In contrast, PTH(1-
34)  treatment greatly increased bone formation in the
reamed limbs (P = 0.055), and this was also seen histolog-
ically (Figure 2A). The strong effects seen with PTH(1-34)
validated the capacity of this model to reveal the effects of
potent bone anabolics.
In a second experiment a wider range of SB431542
doses were used (0.1-10 mg/kg/day). There was concern
that doses higher than 10 mg/kg/day could have toxic or
non-specific effects, as in vitro doses above 20 μM rapidly
induced cell death. For the analysis, to reduce the con-
founding impact of intra-mouse variation in femoral
BMC, the BMC in the marrow ablated limb was calcu-
lated relative to the non-operated (unreamed) limb.
Again, a consistent increase was seen in BMC with mar-
row ablation, although none of the SB431542 treated
groups showed a significant increase in BMC compared
Table 1: Runx2, Alp and Ocn expressions in day 3 samples (fold-change in gene expression)
(A) Runx2 expression in day 3 samples (fold-change in gene expression)
0 μM SB431542 5 μM SB431542
no BMP-2/TGF-β1 1.00 (0.11) 1.77 (0.15)
50 ng/ml BMP-2 1.62 (0.10) 3.59 (0.34)
5 ng/ml TGF-β1 0.54 (0.10) 2.01 (0.09)
50 ng/ml BMP-2, 5 ng/ml TGF-β1 0.56 (0.12) 2.05 (0.23)
(B) Alp expression in day 3 samples (fold-change in gene expression)
0 μM SB431542 5 μM SB431542
no BMP-2/TGF-β1 1.00 (0.13) 3.51 (0.25)
50 ng/ml BMP-2 5.50 (1.25) 11.05 (0.29)
5 ng/ml TGF-β1 0.15 (0.04) 0.92 (0.08)
50 ng/ml BMP-2, 5 ng/ml TGF-β1 0.27 (0.05) 3.47 (0.38)
(C) Ocn expression in day 10 samples (fold-change in gene expression)
0 μM SB431542 5 μM SB431542
no BMP-2/TGF-β1 1.00 (0.06) 1.45 (0.25)
50 ng/ml BMP-2 4.11 (0.28) 5.18 (0.34)
5 ng/ml TGF-β1 0.06 (0.01) 0.70 (0.03)
50 ng/ml BMP-2, 5 ng/ml TGF-β1 0.69 (0.06) 3.72 (0.06)Schindeler et al. BMC Musculoskeletal Disorders 2010, 11:105
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to DMSO controls (Figure 2B). SB431542 treatment did
not have an effect on BMC in the non-operated limb.
Effects of SB431542 in a BMP-2 induced bone formation 
model
As an alternative method for inducing bone formation,
PDLLA polymer pellets containing BMP-2 were
implanted intramuscularly in quadriceps of C57BL6/J
mice. In addition to the BMP-only control group, two
other groups were supplemented with low dose (92 μg)
and high dose (384 μg) SB431542. The BMP-2 doses were
based on previous experience with the model system [25]
and local SB431542 doses were extrapolated from the
ratio of BMP-2:SB431542 used in vitro. Bone formation
occurred over 3 weeks. Two mice were excluded at the
experimental endpoint as misplacement or shifting of the
pellet had led to the ectopic bone fusing with the femur.
The bone volume of the entire pellet was visualized and
quantified by microCT. The low dose SB431542 group
showed a 47% reduction in bone volume compared to the
BMP-only control group (P = 0.06). The higher dose
SB431542 group was comparable to the BMP-only group
(P = 0.21) (Figure 3A). Neither group supported the ini-
tial hypothesis that SB431542 could increase BMP-2
induced bone formation. For representative pellets,
transaxial sections in the centers of the pellets were
reconstructed to create 3 D models (Figure 3B).
Discussion
The study by Maeda et al. (2004) used an in vitro system
to characterize the response of myogenic progenitors to
BMP signaling and treatment with SB431542 [23]. They
showed that SB431542 enhanced the effects of BMP-2 on
osteogenesis and that this was associated with increased
SMAD1 signaling and decreased SMAD2 signaling. Our
data using the MC3T3-E1 cell line supports a pro-osteo-
genic effect of SB431542 on pre-osteoblasts, even in the
absence of exogenous BMP-2. In terms of a screening sys-
tem for novel compounds, the MC3T3-E1 system is
rapid, low-cost, and suitable for generating rapid dose
response curves. Due to limitations with this cell line
[30,31], prospective agents should also be trialed on pri-
mary mesenchymal stem cells, however in the case of
SB431542 this data was already available [23]. Maeda et al
also examined the expression of I-SMADs (inhibitory
SMADs), which are downstream negative regulators of R-
SMAD signaling, and showed a suppression of SMAD6
and SMAD7 by SB431542 with prolonged treatment [23].
While I-SMADs represent potentially important modifi-
ers of R-SMAD signaling, they are transcriptionally regu-
lated by and secondary to the initial R-SMAD response.
Our in vitro data indicates that BMP and TGF-β signals
can modulate R-SMAD signaling in a non-canonical fash-
ion. Specifically, ALK-4/5/7 inhibition led to increases in
pSMAD1 levels and BMP-2 treatment led to a reduction
in pSMAD2 levels (Figure 1).
In this study we have also employed two rapid surgical
models to screen for pro-osteogenic effects in a bone for-
mation/bone repair context. The first was a marrow abla-
tion model previously described in the context of
biglycan null mice that show decreased bone formation
following reaming [29]. We adopted a high-resolution
multi-slice pQCT scanning approach for quantification,
which was found to give more accurate results than indi-
vidual sections that were more susceptible to positional
effects. We confirmed that reaming consistently induced
new bone formation in all groups. PTH(1-34) administra-
tion further increased the amount of bone on the reamed
side, validating the model system. In contrast, SB431542
Figure 2 Radiographic analysis of the marrow ablation model. 
This model utilizes femoral reaming to induce new bone formation 
with femora harvested at day 10. Representative X-rays and histologi-
cal sections (A) of DMSO vehicle, 1 mg/kg/day SB431542, and 25 μg/
kg/day PTH1-34 treated groups are shown. Radiographs illustrate an 
overall increase an intramedullary bone with reaming throughout the 
operated limb, particularly with PTH1-34 treatment. This is also seen be-
low the growth plate (oriented to the left) in histological sections with 
bone stained with Picrosirius red. To test and quantify the effects of a 
range of inhibitor doses in this model, DMSO vehicle, 0.1-10 mg/kg/
day SB431542, and 25 μg/kg/day PTH1-34 treated groups were analyzed 
by pQCT (B). The marrow ablation-induced bone was analyzed by cal-
culating the average BMC of reamed limbs relative to unreamed limbs. 
Only PTH1-34 treatment created a significant increase in reaming-in-
duced bone formation (P = 0.05).Schindeler et al. BMC Musculoskeletal Disorders 2010, 11:105
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did not produce any substantive pro-osteogenic effect in
reamed bones or in non-operated limbs.
The second model was a BMP-2 intramuscular implan-
tation model [25], which contains an endochondral bone
formation component. Again, no significant increase was
observed in bone formation with SB431542 treatment,
rather a trend was seen towards reduced bone with local
dosing (Figure 3).
The lack of a beneficial effect of the TGF-β inhibitor
SB431542 in the in vivo models may be due to several rea-
sons. One possibility was an inappropriate dose selection,
although higher doses were likely to non-specifically
affect other receptors. In a previously published study, a
single dose of 0.2 mg/kg was used to affect metabolic
changes in rats [32], indicating that our dose range of up
to 10 mg/kg/day should be capable of producing signifi-
cant physiological effects in mice. This SB431542 com-
pound has also been successfully used in organ culture
experiments to produce developmental effects [33]. Nev-
ertheless, the specificity and/or bioavailability of
SB431542 may be suboptimal for in vivo studies, and
there certainly exists the potential for more specific
inhibitor compounds to produce improved results.
An alternative explanation for the disparity between in
vitro and in vivo results may be due to the fundamental
differences between the techniques and outcome mea-
sures in the different systems. Cell culture models focus
primarily on the process of cell differentiation, generally
on committed bone cells [11-14,23]. In contrast, surgical
models also incorporate elements of osteoprogenitor
recruitment and proliferation. In the context of TGF-β,
this may be critical as TGF-β release has been recently
shown to play a major role in the recruitment of osteo-
progenitors for bone homeostasis [34]. Thus our study
may highlight a basic limitation of in vitro systems and
stress the utility of expediting screens with surgical mod-
els such as the marrow ablation or BMP-2 implantation
model.
Conclusions
Our data confirms that TGF-β inhibition can enhance the
differentiation of committed osteoprogenitors in culture,
and these effects were additive with BMP-2 treatment.
However, these cell culture phenomena did not translate
into increased bone formation in a marrow ablation or
BMP-induced ectopic bone models. This may be due to
effects of TGF-β on osteoprogenitor recruitment that are
not modeled in vitro. Findings from marrow ablation and
BMP-2 implantation models suggest that sustained global
TGF-β suppression with SB431542 is likely to be ineffec-
tive for orthopaedic applications.
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